Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
The latest news, research, and perspectives in myeloproliferative neoplasms (MPNs). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Leah SherwoodMyeloproliferative Neoplasms | December 1, 2022
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
Read More
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
The National Comprehensive Cancer Network publishes new MPN guidelines.
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
Researchers published new classifications for MPNs and acute leukemias.
Leah SherwoodMyeloproliferative Neoplasms | November 29, 2022
Those with MF with high molecular and cytogenetic risk do not benefit from higher intensity conditioning before transplant.
Cecilia BrownMyeloproliferative Neoplasms | November 16, 2022
Transfusion independence was associated with improved survival in studies of momelotinib in patients with myelofibrosis.
Cecilia BrownMyeloproliferative Neoplasms | November 16, 2022
Adding navitoclax to ruxolitinib led to durable spleen volume reductions and improved total symptoms in myelofibrosis.
Cecilia BrownMyeloproliferative Neoplasms | November 16, 2022
There are several risk factors for thrombosis and major bleeding in patients with myelofibrosis, according to a recent study.
Leah SherwoodMyeloproliferative Neoplasms | October 28, 2022
A large analysis of real-world treatment outcomes in patients with myelofibrosis who were treated with ruxolitinib.
Leah SherwoodMyeloproliferative Neoplasms | October 28, 2022
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol.
Leah SherwoodMyeloproliferative Neoplasms | October 28, 2022
As TKIs have become available to patients, survival for those with CML has significantly improved but disparities.
Leah SherwoodMyeloproliferative Neoplasms | October 27, 2022
VERIFY, a phase III trial of the hepcidin mimetic rusfertide (PTG-300), is now enrolling patients with PV.
Leah SherwoodMyeloproliferative Neoplasms | October 27, 2022
IFN alpha-2 influences the regulation of several ECM genes involved in tissue remodeling.
Kerri FitzgeraldMyeloproliferative Neoplasms | October 20, 2022
A recent case study found evidence of an acquired in utero mutation in monozygotic twins who presented with CALR.
Kerri FitzgeraldMyeloproliferative Neoplasms | October 20, 2022
A new prognostic model identified risk factors for reduced survival in patients with myelofibrosis who received ruxolitinib.
Kerri FitzgeraldMyeloproliferative Neoplasms | October 20, 2022
The EXPAND study supports the use of ruxolitinib 10 mg twice daily in patients with MF.
Kerri FitzgeraldMyeloproliferative Neoplasms | October 20, 2022
A large real-world study assessed patients who were diagnosed with myeloproliferative neoplasms before age 25.
Leah SherwoodMyeloproliferative Neoplasms | October 12, 2022
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Leah SherwoodMyelodysplastic Syndromes | June 23, 2022
Study finds BM CH was present in nearly two-thirds of BPDCN patients and particularly prevalent in elderly patients.
Kerri FitzgeraldMyeloproliferative Neoplasms | June 23, 2022
Pankit J. Vachhani, MD, and Srdan Verstovsek, MD, debate the usefulness of variant allele frequency (VAF).
Leah LawrenceMyeloproliferative Neoplasms | June 13, 2022
Long-term results from the RESPONSE-2 trial confirm efficacy of ruxolitinib for PV.
Advertisement
Editorial Board

Advertisement